Yale University
New Haven, CT, United States
Dr. Carrie L. Lucas received her PhD from Harvard Medical School and her postdoctoral training from the National Institutes of Health, NIAID. The Lucas laboratory is devoted to discovering new and translationally relevant principles of immunology by defining and studying severe immune disorders. Combining human genomics, in vitro studies using primary patient cells, and in vivo mouse modeling approaches, her team seeks to gain incisive basic and translational insights starting with patients. The lab’s focus on primary immunodeficiencies has largely centered around phosphoinositide 3-kinase (PI3K) signaling and disease mechanisms and treatments in patients with mutations in PI3K subunits, including ‘Activated PI3K-delta Syndrome’ (APDS) and ‘Inactivated PI3K-gamma Syndrome’ (IPGS). More recently, the lab has added an emphasis on studying inflammatory diseases, including SARS-CoV-2-associated ‘multisystem inflammatory syndrome in children’ (MIS-C) and vaccine-associated myocarditis. A major current effort centers on new biology illuminated by a monogenic autoinflammatory disease we named ‘Deficiency in ELF4, X-linked’ (DEX). The rare diseases we study uniquely enable us to gain in-depth mechanistic insights into human immunology, thereby providing translational knowledge to improve understanding and treatment of a broader set of common diseases with immune involvement.
Immunobiology Illuminated by Genetic Errors of Immunity
Tuesday, November 14, 2023
12:15 PM – 12:30 PM PT
Disclosure(s): Ono Pharma: Grant/Research Support (Ongoing); Pharming Healthcare: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing)